Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab-R-GemOx With Consolidative ASCT and Additional Epcoritamab in Relapsed/Refractory Transplant-Eligible DLBCL
NCT07365306Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Jul 2026
- Primary completion
- Oct 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL), sponsored by City of Hope. Started Jul 2026; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT07365306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07365306.